4.6 Article

Improving Awareness, Identification, and Management of Meibomian Gland Dysfunction

期刊

OPHTHALMOLOGY
卷 119, 期 10, 页码 S1-S12

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2012.06.064

关键词

-

资金

  1. The New York Eye and Ear Infirmary
  2. MedEdicus LLC
  3. Alcon, Inc
  4. Bausch & Lomb Incorporated
  5. Santen Pharmaceutical Co, Ltd.

向作者/读者索取更多资源

Ocular surface disorders-and dry eye, in particular-is a leading reason for visits to eye care professionals. It has been generally accepted that meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye, as well as being associated with aqueous-deficient dry eye. Yet, researchers and clinicians have lacked a global consensus on the definition of MGD, its epidemiology, pathophysiology, and management. Various systemic diseases and medications have been associated with the progression of both dry eye and MGD, as have several ocular disorders beyond those directly affecting the surface. It is in the best interest of patients for clinicians to be able to better identify and diagnose MGD, differentiating it from other ocular surface disorders, and to recognize the effects of MGD on the ocular surface, and thus initiate appropriate therapy. This CME activity provides expert insight into the Tear Film and Ocular Surface Society's International Workshop on MGD consensus report, offering practical application of its findings to better manage MGD patient care, particularly for those patients facing or undergoing ocular surgery. Ophthalmology 2012;119:S1-S12 (c) 2012 by the American Academy of Ophthalmology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据